U.S. markets close in 5 hours 46 minutes

  • S&P 500

    4,697.76
    +14.96 (+0.32%)
     

  • Dow 30

    36,246.53
    +159.08 (+0.44%)
     

  • Nasdaq

    15,886.26
    +32.41 (+0.20%)
     

  • Russell 2000

    2,392.25
    -8.68 (-0.36%)
     

  • Crude Oil

    80.66
    -0.22 (-0.27%)
     

  • Gold

    1,860.20
    -6.40 (-0.34%)
     

  • Silver

    25.03
    -0.07 (-0.28%)
     

  • EUR/USD

    1.1356
    -0.0015 (-0.14%)
     

  • 10-Yr Bond

    1.6220
    -0.0010 (-0.06%)
     

  • GBP/USD

    1.3442
    +0.0029 (+0.21%)
     

  • USD/JPY

    114.4610
    +0.3320 (+0.29%)
     

  • BTC-USD

    60,945.58
    -3,837.07 (-5.92%)
     

  • CMC Crypto 200

    1,496.83
    -10.55 (-0.70%)
     

  • FTSE 100

    7,332.46
    -19.40 (-0.26%)
     

  • Nikkei 225

    29,808.12
    +31.32 (+0.11%)
     

Global Industry Analysts Predicts the World Electroceuticals / Bioelectric Medicine Market to Reach $20.8 Billion by 2026

·7 min read

SAN FRANCISCO, Nov. 16, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Electroceuticals / Bioelectric Medicine - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

World Electroceuticals / Bioelectric Medicine Market
World Electroceuticals / Bioelectric Medicine Market

FACTS AT A GLANCE
Edition: 8; Released: November 2021
Executive Pool: 10947
Companies: 50 - Players covered include Abbott Laboratories; Biotronik SE & Co. KG; Boston Scientific Corporation; Cochlear Ltd.; electroCore, Inc.; LivaNova PLC; Medtronic PLC; Nevro Corp.; Second Sight Medical Products, Inc.; Sonova Holding AG and Others.
Coverage: All major geographies and key segments
Segments: Product (Cardiac Pacemakers & ICDs, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Other Products); End-Use (Hospitals, Clinics & ASCs; Other End-Uses)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry

ABSTRACT-

Global Electroceuticals / Bioelectric Medicine Market to Reach US$20.8 Billion by the Year 2026
Electroceuticals have a lot of potential to become the principal method of medical treatment. The relatively new area of Bioelectric medicine/Electroceutical devices has provided a new approach to treatment of chronic illnesses. As the treatment is through electrical impulses rather than drugs, there is less chance of major side effects and further, the therapy also results in the body producing endorphins which gives relief from pain. This new form of treatment through devices can address resynchronization, defibrillation and pacemaker application normally used in the field of cardiology. The technology also has its use in treating heart failure, atrial fibrillation, diseases related to the coronary artery, myocarditis, resistant hypertension, ventricular as well as atrial tachyarrhythmias, pulseless electrical activity and refractory angina. The heightened pace of research in the area of bioelectric medicine is also likely to boost future business. Companies are exploring on non-surgical methods of implantation and improved features of electrode technologies for making the embedding process of the biomedicines possible through the skin. Such non-invasive electroceutical devices also show promising future due to the comfort factor attached to them for patients who do not have to incur surgical costs and inconvenience of post-surgery recovery.

Amid the COVID-19 crisis, the global market for Electroceuticals / Bioelectric Medicine estimated at US$15 Billion in the year 2020, is projected to reach a revised size of US$20.8 Billion by 2026, growing at a CAGR of 5.6% over the analysis period. Cardiac Pacemakers & ICDs, one of the segments analyzed in the report, is projected to grow at a 6.5% CAGR to reach US$13.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cochlear Implants segment is readjusted to a revised 4.6% CAGR for the next 7-year period. This segment currently accounts for a 14.8% share of the global Electroceuticals / Bioelectric Medicine market. Cardiac diseases have increased globally, fueling the market growth of the cardiac pacemaker. A cardiac pacemaker when placed in the chest uses electrical pulses to control arrhythmia or abnormal heart rhythm of patients. Cochlear implant is one of the most common electroceutical for substituting damaged ear part and providing hearing ability.

The U.S. Market is Estimated at $6.9 Billion in 2021, While China is Forecast to Reach $1.7 Billion by 2026
The Electroceuticals / Bioelectric Medicine market in the U.S. is estimated at US$6.9 Billion in the year 2021. The country currently accounts for a 44.6% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$1.7 Billion in the year 2026 trailing a CAGR of 6.7% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR while Rest of European market (as defined in the study) will reach US$1.8 Billion by the end of the analysis period. North America, with its well-developed healthcare infrastructure, is widespread adopter of new technologies, thus providing favorable growth outlook for electroceuticals/ bioelectric medicine technology. The growing number of people suffering from a range of chronic medical conditions like cardiovascular disease, neurological ailments, cancer, arrhythmia, and hearing loss are propelling growth in the region. The presence of leading medical device makers including Boston Scientific Corporation, Medtronic and BIOTRONIK in the region augurs well for the market. In Europe, the substantial infrastructure for healthcare, high demand for innovative medical solutions and the presence of several healthcare majors in Germany, the UK, Switzerland, and France, are presenting robust growth opportunities.

Spinal Cord Stimulators Segment to Reach $2.9 Billion by 2026
A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord. Spinal cord stimulators consist of electrodes, or leads, placed in the epidural space around the spinal cord. The electrodes are connected to and powered by a pulse generator or batteries. In the global Spinal Cord Stimulators segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.9 Billion in the year 2020 will reach a projected size of US$2.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$205.4 Million by the year 2026. More

MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android

About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: ZA@StrategyR.com

LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp

Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitter
https://twitter.com/marketbytes

Journalists & Media
Info411@strategyr.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-industry-analysts-predicts-the-world-electroceuticals--bioelectric-medicine-market-to-reach-20-8-billion-by-2026--301424767.html

SOURCE Global Industry Analysts, Inc.

Recommended Stories

  • After a Pullback, Marathon Digital (NASDAQ:MARA) Presents a High Risk - High Reward Opportunity

    Few asset classes can match the volatility of cryptocurrencies. Naturally, companies like Marathon Digital Holdings, Inc. (NASDAQ: MARA)that operate in that space peg themselves to the volatility. Interestingly enough, despite the drop of 27% in a single session, this move has undone just two weeks of market movement.

  • Nvidia Stock Before Earnings: Buy, Hold, or Sell?

    Wall Street got jittery last week as Wedbush Securities analyst Matt Bryson downgraded Nvidia (NASDAQ: NVDA) stock from outperform to neutral on Friday, Nov. 6, citing the company's sky-high valuation. Bryson admitted that he doesn't see any negative factors affecting Nvidia and remains positive about the company's prospects. Interestingly, the Wedbush analyst raised his price target on Nvidia stock from $220 to $300.

  • These 2 High-Growth Stocks Just Plunged. Are They Still Buys?

    Take for example both Lemonade (NYSE: LMND) and Upstart Holdings (NASDAQ: UPST). Lemonade posted a mostly outstanding quarter. In force premium, which has the complicated definition of "average aggregate annual premium," and is calculated by multiplying total customer count by average premium per customer, increased 84% year over year.

  • Walmart and Home Depot beat earnings estimates, post strong inventories amid supply chain issues

    Yahoo Finance’s Julie Hyman and Brian Sozzi discuss earnings for Walmart and Home Depot, as well as the outlook for those retailers as the holiday season approaches.

  • 2 Big Dividend Stocks Yielding 9%; Analysts Say ‘Buy’

    With just seven weeks left in 2021, Wall Street’s big names are firming up their year-end forecasts. Mike Wilson, chief U.S. equity strategist at Morgan Stanley, has set a 4,400 target for the S&P 500 by the end of 2022. That implies a fall of 6% from current levels. In his forecast, Wilson points out the factors that are likely to weigh on the markets, including “uncertainty around that expectation goes up materially given cost pressures, supply issues, along with tax and policy uncertainty tha

  • 10 Reddit Stocks to Buy in November

    In this article, we discuss the 10 Reddit stocks to buy in November. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit Stocks to Buy in November. Retail traders, who often use internet platform Reddit to exchange investment ideas, have helped push the social media firm into […]

  • Jim Cramer Stock Portfolio: 10 Recent Additions

    In this article, we discuss the 10 recent additions to the stock portfolio of Jim Cramer. If you want to skip our detailed analysis of these stocks, go directly to the Jim Cramer Stock Portfolio: 5 Recent Additions. Jim Cramer, the host of Mad Money on CNBC and a former hedge fund manager, has built […]

  • Peloton stock ticks up after the fitness company files to sell $1 billion worth of shares

    Yahoo Finance’s Julie Hyman and Brian Sozzi discuss Peloton’s plans to sell an additional $1 billion worth of shares.

  • Why Workhorse Group Rallied Even After Reporting Negative Q3 Revenue

    Nearly all the news offered by electric vehicle (EV) maker Workhorse Group (NASDAQ: WKHS) during its third-quarter (Q3) earnings report on Nov. 9 was downbeat, ranging from negative revenue to stopping sales of its main product. During the earnings conference call, Dauch said the C1000 would be thoroughly reviewed during first-quarter 2022.

  • Estimating The Intrinsic Value Of Big 5 Sporting Goods Corporation (NASDAQ:BGFV)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Big 5 Sporting Goods...

  • Sea Ltd. Quarterly Earnings A Miss But Stock Nears Buy Point

    SE stock touched a buy point as the Asian e-commerce and gaming company reported third-quarter results early Tuesday.

  • Cathie Wood strongly disputes Jack Dorsey’s ‘hyperinflation’ warning, but they agree on one asset class — in any market environment

    Many predict this asset will be a great hedge against inflation.

  • Why 23andMe Stock Crashed 10% Today

    Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had a good week last week, surging more than 13% in response to a positive second-quarter 2022 earnings report Thursday. Things got even worse today, when investors responded to a downgrade of 23andMe stock by a Citigroup analyst -- by selling off the stock by 10.1% (as of 11:30 a.m. EST). In my own note on the company last week, I pointed out that sales growth at 23andMe was a weak 7% in Q2, down steeply from Q1's 23% growth pace.

  • Splunk Stock Slumps and Cathie Wood’s ARK Buys the Drop

    Cathie Wood’s Ark Next Generation Internet ETF buys nearly 120,000 shares of Splunk after the stock tumbles following the departure of the software company’s CEO.

  • Is EVgo Stock a Buy?

    Several EV charging companies are working hard to capture a share of this growing market. EVgo (NASDAQ: EVGO), which went public in July, is expanding its network fast. There are two ways to look at the EV charging industry.

  • 10 Best Large-Cap Stocks to Buy According to Columbus Hill Capital Management

    In this article, we discuss the 10 best large-cap stocks to buy according to Columbus Hill Capital Management. You can skip our detailed analysis of the hedge fund’s performance and go directly to read the 5 Best Large-Cap Stocks to Buy According to Columbus Hill Capital Management. Columbus Hill Capital Management is a hedge fund […]

  • 3 Top Stocks to Buy if There Is a Market Pullback

    Microsoft (NASDAQ: MSFT) currently holds the honor as the largest publicly traded company on the planet by market capitalization. As awesome as Microsoft is as a company, it is rapidly running into a problem caused by the law of large numbers. Microsoft currently trades at more than 10 times its anticipated 2023 revenue and around 32 times its anticipated 2023 earnings.

  • 10 Best Cheap Technology Stocks To Invest In

    In this article, we discuss the 10 best cheap technology stocks to invest in. You can skip our detailed analysis of the technology sector, and go directly to read the 5 Best Cheap Technology Stocks To Invest In. As the financial markets crashed during the pandemic in 2020, investors remained bullish on tech stocks throughout […]

  • Walmart Stock Trades Lower. Retail Giant Beats Estimates and Boosts Guidance.

    Walmart reports third-quarter sales of $140.5 billion. U.S. same-store sales, excluding fuel, rise 9.2%.

  • Why Gores Guggenheim's Shares Popped 15.4% Today

    Shares of Gores Guggenheim (NASDAQ: GGPI), a special-purpose acquisition company (SPAC) that is planning to merge with electric-car company Polestar, jumped as much as 28.1% in trading on Monday after filing a Form F-4 with the Securities and Exchange Commission (SEC). Polestar says it has 35 permanent locations with plans to expand to over 150 locations by the end of 2023. Given Polestar's potentially rapid ramp up to becoming a major EV supplier, this could be a great way to play the industry.